Skip to main content
Loading

Early-stage characterization and selection of immuno-oncology leads through in-vitro cell-based assays and beyond

24 Sep 2024
Muir Woods
Translational Research
Early-stage characterization and selection of immuno-oncology leads through in-vitro cell-based assays and beyond
  • From checkpoint inhibitors towards neoepitope vaccines, does one size fits it all?
  • Fit for purpose in vitro assay development
  • Early characterization and immunogenicity testing of lead candidates
  • Non human primate in vitro assays
Industry Expert
Sofie Pattyn, Chief Technology Officer & Founder - ImmunXperts